Effect of CT manifestations of cholesteatoma on MMP‑2, MMP‑9 and IL‑6 in the serum of patients

Abstract

Effect of CT manifestations of cholesteatomatous otitis media on matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and interleukin-6 (IL-6) in the serum of patients was investigated. A total of 176 patients with cholesteatomatous otitis media were enrolled as the study group and 181 patients with simple otitis media were enrolled as the control group. Patients were admitted to the Changxing People's Hospital from January 2010 to December 2016. The patients in the study group were classified according to the 64-row spiral CT diagnosis. The expression levels of MMP-2, MMP-9 and IL-6 in the serum of the selected patients were detected by ELISA. MMP-2, MMP-9 and IL-6 expression levels in the study group were higher than those in the control group (P<0.05). MMP-2, MMP-9 and IL-6 expression levels in the serum of the patients with injured ossicular chain were significantly higher than those in the serum of patients with injured malleus or incus (P<0.05), and significantly higher than those in the serum of patients with intact ossicular chain (P<0.05). The levels of MMP-2, MMP-9 and IL-6 in the serum of the patients whose malleus or incus was injured were higher than those in the serum of the patients with intact ossicular chain (P<0.05). There was an obvious positive correlation between the injury degree of different sclerotins in CT manifestations of the patients in the study group and MMP-2, MMP-9, and IL-6 (P<0.05). The high expression levels of MMP-2, MMP-9 and IL-6 in the serum of patients with cholesteatomatous otitis media were positively correlated with the injury degree of ossicle, which may be a sign of poor prognosis of cholesteatomatous otitis media.

IL‑1α, IL‑6 and IL‑8 serum values in patients with chronic suppurative otitis media

“…Similar results with elevated serum IL-6 levels were obtained in a recent study showing that IL-6, metalloproteinase-2 and metalloproteinase-9 are related to the degree of destruction in the middle ear and the severity of the disease (15).…”

Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review

“…One study analyzed the expression of cytokeratins, TP53 and Matrix Metalloproteinasis-9 (MMP9) through quantitative real-time PCR [ 16 ]. Only one study evaluated serum level of MMP-2, MMP-9, and IL-6 in patients with COM [ 19 ].…”

“…In general, the phenotype defines any clinical observable features of a disease, without establishing a direct etiologic relationship with a distinct pathophysiologic mechanism, whereas the endotype describes different subgroups that share the same pathophysiologic processes leading to the development, the progression, and the presentation of a disease. Currently, only a few studies are available in the literature about biomarkers of C, some of which are mainly related to its etiopathogenesis and others to its clinical features as recurrence disease and bony erosion [ 2 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ].…”

miR-199a Targeting PNRC1 to Promote Keratinocyte Proliferation and Invasion in Cholesteatoma

“…Cholesteatoma is known as a severe chronic middle ear disease that occurs in the middle ear, eventually causing adverse complications with rapid growth and bone resorption [ 23 ]. It accounts for 0.5–1.8% of all brain tumors [ 24 ]. Elucidating the underlying molecular mechanism for the progression of cholesteatoma will help provide more treatment options for this disease.…”